Evaluation of online teaching modules for PSMA PET interpretation

Area of Science:

• Nuclear Medicine
• Radiology
• Oncology

Background:

• US FDA approval of multiple prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agents for prostate cancer evaluation.
• Growing understanding of interpretive pitfalls associated with PSMA-PET imaging.
• Development of numerous online training modules for interpreting these agents.

Purpose of the Study:

• To evaluate the content and approach of online training modules for US FDA-approved PSMA-PET imaging agents.
• To identify potential sources of variability in clinical reporting due to differences in reader training.

Main Methods:

• Examination of websites from marketers of FDA-approved PSMA-PET agents (⁶⁸Ga-PSMA-11 [Illuccix, Locametz] and ¹⁸F-rh-PSMA-7.3 [Posluma]).
• Review of training materials (videos, PDFs, PowerPoint presentations) from the Society of Nuclear Medicine and Molecular Imaging website for ¹⁸F-DCFPyL (Pylarify).
• Analysis of interpretive approaches, tips, and pitfalls covered in each training module.

Main Results:

• Training module video lengths varied substantially, from 20 to 315 minutes.
• Each module presented a distinct approach to PSMA PET scan findings.
• Modules covered a variable number and breadth of interpretive tips and pitfalls (approximately 12-30 total).

Conclusions:

• All four PSMA PET reader training modules addressed critical interpretive pitfalls.
• Considerable variation in module length suggests differing time commitments for completion.
• Discrepancies among training modules and the specific radiotracer used may contribute to reader inconsistency in clinical practice.